-

SABCS 2024 | Dr. Cuizhi Geng: How to Scientifically Manage Overweight/Obesity in Early-Stage Breast Cancer Patients
Breast cancer patients may experience overweight or obesity during treatment due to medication side effects and hormonal fluctuations. What impact does being overweight or obese have on patient prognosis? At the recent San Antonio Breast Cancer Symposium (SABCS), numerous new research findings, clinical practices, and treatment advancements were presented. One study from the Early Breast…
-

SABCS 2024 | Academician Binghe Xu Presents Latest Research in Oral Presentation and Spotlight Poster at San Antonio
The 47th San Antonio Breast Cancer Symposium (SABCS) successfully concluded in San Antonio, USA. On December 11 (local time), during the second day of the conference, Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences delivered a significant presentation in the “General Session 1,” unveiling the latest data from the PHILA study…
-

SABCS 2024 | Dr. Icro Meattini: Exploring Optimal Treatment Strategies for Women Aged 70 and Above with Stage I Luminal Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium (SABCS), Dr. Icro Meattini from the University of Florence, Italy, presented significant findings from the EUROPA trial. This Phase III randomized controlled trial focused on women aged 70 and above with Stage I Luminal breast cancer. The study aimed to compare the effects of radiation therapy (RT)…
-

CACA-GO | Dr. Stephen Freedland: Salvage Treatment Strategies for Biochemical Recurrence in Prostate Cancer from the EMBARK Study
The 14th Shanghai Urologic Oncology Academic Conference and the Annual Meeting of the Chinese Anti-Cancer Association Male Reproductive System Tumor Committee (CACA-GO) took place from December 6–8,2024 in Shanghai. The conference invited several internationally renowned experts in urologic oncology for academic lectures and surgical demonstrations.Dr. Stephen Freedland from Cedars-Sinai Medical Center in the United States…
-

SABCS 2024 | Dr. Ting Luo: Four-Year Benefit Analysis of Perioperative Chemotherapy ± Immunotherapy in Triple-Negative Breast Cancer Patients
The 47th San Antonio Breast Cancer Symposium (SABCS) successfully took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advances, and technological innovations over the past year. Among the presented studies, an oral presentation (GS3-05) analyzed the…
-

SABCS 2024 | Dr. Yan Xue: The SONIA Trial Reveals No Significant Difference in HRQoL Between First-Line and Second-Line Use of CDK4/6 Inhibitors in Advanced Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium (SABCS), a study led by Professor Noor Wortelboer from Erasmus University Medical Center in Rotterdam was presented during the “Poster Spotlight 2: Personalizing CDK 4/6 Inhibitor Therapy for Patients with Metastatic Breast Cancer: Survival, QOL, and Biomarkers” session. This research, based on the SONIA trial data, provided…
-

SABCS 2024 | Dr. Guojun Zhang: Advances in Tumor Genetics and Targeted Drug Development
The 47th San Antonio Breast Cancer Symposium (SABCS) recently concluded successfully in San Antonio, USA. SABCS is the world’s largest conference in the field of breast cancer, attracting more than 10,000 registered participants from 102 countries. Over four days, the conference featured thousands of keynote speeches and research abstracts. On December 11, during the second…
-

2024 Cross-Strait Breast Cancer Forum | Dr. Jian Liu: Building Bridges for Academic Exchange and Exploring New Pathways in Breast Cancer Treatment
The “2024 Cross-Strait Breast Cancer Forum,” held alongside the 2024 Academic Annual Meeting of the Breast Disease Branch of the Fujian Medical Association, the 2024 Annual Meeting of the Oncology Physicians Branch of the Fujian Medical Doctor Association, and the Fujian Breast Cancer Prevention and Treatment Workshop, took place from December 13 to 15, 2024,…